HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies for chronic, low-grade inflammation and related diseases in the United States. Its lead product candidates include HCW11-018b, a tetra-valent T-cell engager; HCW11-040, a multifunctional fusion molecule combining cytokines and pembrolizumab; and HCW9302, an injectable interleukin 2 (IL-2) fusion protein complex in clinical trials for alopecia areata. The company also develops HCW9201 and HCW9206, fusion proteins intended as reagents for producing natural killer (NK) cell-based therapies and CAR therapies for infectious diseases, respectively, as well as HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. for cell therapy-based treatments and a license, research and co-development agreement with WY Biotech Co., Ltd. for a preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
USA